Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
Go Saito, Yuko Oya, Yoshihiko Taniguchi, Hayato Kawachi, Daichi Fujimoto, Hirotaka Matsumoto, Shunichiro Iwasawa, Hidekazu Suzuki, Takayuki Niitsu, Eisaku Miyauchi, Takashi Yokoi, Toshihide Yokoyama, Takeshi Uenami, Yoshihiko Sakata, Daisuke Arai, Asuka Okada, Kenji Nagata, Shunsuke Teraoka, Masaki Kokubo
Topics & Concepts
DurvalumabMedicinePneumonitisChemoradiotherapyLung cancerRadiation therapyInternal medicineLungCancerNivolumabImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis